Radiation proctitis represents a significant clinical concern for patients who have undergone pelvic radiotherapy, whether as part of a curative effort for prostate, cervical, or colorectal cancer or as a palliative measure. This condition arises when the therapeutic ionizing radiation intended for malignant cells damages the normal tissues of the rectum, leading to inflammation, fibrosis, and a spectrum of bothersome lower gastrointestinal symptoms. Understanding the pathophysiology, risk factors, and management strategies is essential for both oncologists and gastroenterologists to mitigate long-term morbidity.
Pathophysiology and Mechanism of Injury
The fundamental issue in radiation proctitis is the imbalance between endothelial cell damage and the reparative capabilities of the microvasculature within the rectal wall. High-energy radiation generates reactive oxygen species that cause direct DNA damage to rapidly dividing cells, including the endothelial cells lining the rectal mucosa. This injury triggers a cascade of inflammatory cytokines and subsequent oxidative stress, which progressively leads to vascular occlusion, mucosal atrophy, and eventual fibrosis. The reduced blood flow impairs the tissue's ability to heal, making the rectum particularly susceptible to chronic injury long after the external beam treatment has concluded.
Clinical Presentation and Symptoms
Patients typically manifest symptoms within the initial weeks of treatment, though a subset may experience a latent phase lasting years before developing chronic issues. The hallmark of acute radiation proctitis is rectal bleeding, which is often bright red and coincides with an increased frequency of bowel movements and a sense of urgency. As the condition progresses to a chronic state, symptoms shift toward persistent bleeding, mucus discharge, and tenesmus—the painful spasm of the rectal muscles giving the feeling of incomplete evacuation. In severe, long-standing cases, strictures or fistulae may form, significantly altering the patient’s quality of life.
Identifying Risk Factors
Not all patients receiving identical radiation doses will develop the same severity of symptoms, highlighting the role of individual risk factors. Key determinants include the total radiation dose, the fractionation schedule, and the specific volume of the rectum exposed to high-dose radiation. Concurrent chemotherapy, such as 5-fluorouracil or mitomycin C, acts as a potent radiosensitizer, increasing the likelihood of injury. Additionally, factors such as smoking, diabetes, and prior pelvic surgery can compromise the vascular reserve of the rectum, making it less resilient to the ischemic effects of radiotherapy.
Diagnostic Evaluation
Reaching a diagnosis of radiation proctitis requires a careful integration of the patient’s history and objective findings. A thorough proctoscopy or flexible sigmoidoscopy is often the first step, allowing the clinician to visualize the characteristic mucosal changes, such as pallor, friability, and telangiectasias. While a biopsy can confirm the diagnosis by revealing features like crypt distortion and chronic inflammatory infiltrate, it must be performed cautiously to avoid creating a non-healing wound. In cases of significant bleeding or suspected stricture, a contrast enema or pelvic MRI may be utilized to assess the anatomy and rule out other pathologies.
Management and Treatment Strategies
The therapeutic approach to radiation proctitis is largely symptomatic, aiming to control bleeding and improve bowel function. For mild cases, conservative measures such as dietary modifications to increase stool bulk and the use of topical therapies like sucralfate enemas can be effective. More advanced bleeding may be addressed with endoscopic interventions, including argon plasma coagulation (APC) or band ligation, which target the bleeding vessels directly. In refractory cases, systemic options like hyperbaric oxygen therapy or anti-angiogenic agents may be considered to promote healing and reduce inflammation.
